Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-phenylalanine is the D-enantiomer of phenylalanine and a synthetic amino acid not found in significant amounts in natural proteins. It has been marketed as a prescription drug under various brand names and is primarily used for its potential antidepressant and analgesic effects. The main mechanism of action is believed to be inhibition of enkephalinase enzymes that degrade endogenous opioid peptides called enkephalins. This inhibition may increase levels of enkephalins in the body, leading to anti-inflammatory and analgesic effects. Some studies also suggest possible anti-craving properties. While it has been used clinically in Argentina since at least the 1970s as an antidepressant and pain modulator, robust clinical evidence supporting its efficacy remains limited[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-Phenylalanine.